Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to nutrient intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 agents exhibit promising therapeutic efficacy in treating type